Benitec Biopharma Inc. financial data

Symbol
BNTC on Nasdaq
Location
Hayward, CA
Fiscal year end
30 June
Latest financial report
10-Q - Q4 2025 - 12 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3568% % 168%
Debt-to-equity 3.3% % -59%
Return On Equity -33% % 31%
Return On Assets -32% % 28%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34,354,334 shares 46%
Common Stock, Shares, Outstanding 34,254,907 shares 46%
Entity Public Float $152,964,292 USD 1727%
Common Stock, Value, Issued $3,000 USD 50%
Weighted Average Number of Shares Outstanding, Basic 45,970,516 shares 23%
Weighted Average Number of Shares Outstanding, Diluted 45,970,516 shares 23%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $18,051,000 USD 20%
General and Administrative Expense $25,151,000 USD 124%
Operating Income (Loss) $43,202,000 USD -64%
Nonoperating Income (Expense) $4,241,000 USD 59%
Net Income (Loss) Attributable to Parent $38,961,000 USD -65%
Earnings Per Share, Basic -0.93 USD/shares -123%
Earnings Per Share, Diluted -0.93 USD/shares -123%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $188,790,000 USD 141%
Other Assets, Current $562,000 USD 54%
Assets, Current $189,595,000 USD 141%
Property, Plant and Equipment, Net $115,000 USD -24%
Operating Lease, Right-of-Use Asset $905,000 USD 561%
Other Assets, Noncurrent $11,000 USD -74%
Assets $190,681,000 USD 141%
Employee-related Liabilities, Current $483,000 USD -10%
Liabilities, Current $2,801,000 USD -9.3%
Operating Lease, Liability, Noncurrent $519,000 USD
Liabilities $3,320,000 USD 6.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax $883,000 USD -28%
Retained Earnings (Accumulated Deficit) $248,978,000 USD -23%
Stockholders' Equity Attributable to Parent $187,361,000 USD 147%
Liabilities and Equity $190,681,000 USD 141%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,351,000 USD 27%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 160,000,000 shares 0%
Common Stock, Shares, Issued 34,254,907 shares 46%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $3,265,000 USD -119%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $188,903,000 USD 141%
Deferred Tax Assets, Valuation Allowance $25,044,000 USD 22%
Deferred Tax Assets, Gross $25,534,000 USD 22%
Operating Lease, Liability $987,000 USD 620%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $39,156,000 USD -68%
Lessee, Operating Lease, Liability, to be Paid $1,046,000 USD 653%
Property, Plant and Equipment, Gross $1,612,000 USD 1.1%
Operating Lease, Liability, Current $468,000 USD 242%
Lessee, Operating Lease, Liability, to be Paid, Year Two $291,000 USD -4%
Lessee, Operating Lease, Liability, to be Paid, Year One $512,000 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $59,000 USD 2850%
Deferred Tax Assets, Operating Loss Carryforwards $16,473,000 USD 14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Operating Lease, Payments $32,000 USD -56%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $54,000 USD -40%
Share-based Payment Arrangement, Expense $26,412,000 USD 526%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%